Entero Healthcare Solutions Management Guidance Tracker
12 forward-looking guidance items tracked across 3 quarters.
Revenue
Management expects full-year revenue growth of 30%, including ~15% organic and ~15% from M&A, with ~₹500 crore of acquired revenue recognized.
Q3 FY26Full-year like-to-like revenue growth of 30%ActiveManagement confirmed on track to deliver 30% like-to-like revenue growth for FY26, implying ~35% growth in Q4.
Q4 FY26FY27 consolidated revenue growth of 23% (ex-new M&A)ActiveRevenue growth target of 23% YoY, excluding any new acquisitions, driven by calendarization of past deals and organic growth.
Margins
Full-year EBITDA margin target of over 4%, driven by operating leverage, product mix improvement, and procurement efficiencies.
Q3 FY26Full-year EBITDA margin above 4%ActiveEBITDA margin guidance of north of 4% for FY26, requiring Q4 margin of ~4.5% to achieve.
Q3 FY26Medtech acquisitions to add 50-75bps to EBITDA marginsTrackedPost-integration, medtech acquisitions expected to improve overall EBITDA margin by 50-75 basis points on a pro forma basis.
Q4 FY26FY27 EBITDA margin target of 5%ActiveEBITDA margin guided to 5% for FY27, up from 4% in FY26, supported by gross margin expansion and operating leverage.
Other
Targeting a 10% reduction in working capital days from 66 to 60 by end of FY26 through ERP and data science initiatives.
Q1 FY26Tax rate of 17-18% for FY26TrackedEffective tax rate expected to remain in the 17-18% range for the full year due to tax efficiency measures.
Q4 FY26Operating cash flow conversion of at least 50% of EBITDAActiveTarget to convert at least 50% of EBITDA into operating cash flow in FY27, reflecting working capital discipline.
Q4 FY26Minority interest to be ~25% of PAT before minorityActiveMinority interest expected to normalize to ~25% of PAT (pre-minority) in FY27, down from 38% in Q4 FY26.